Factors Influencing Long Term Survival in Metastatic Castration Resistant Prostate Cancer Patients: a Spanish Multicentre Experience.
Background: Cabazitaxel is approved as second line treatment for metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. However, it is difficult to establish which patients will reach benefit. In this study, we aimed to analyze retrospectively clinical characteristics for c...
| Autores: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de documento: | artigo |
| Data de publicação: | 2020 |
| País: | España |
| Recursos: | Universidad de Castilla-La Mancha |
| Repositório: | RUIdeRA. Repositorio Institucional de la UCLM |
| OAI Identifier: | oai:ruidera.uclm.es:10578/47612 |
| Acesso em linha: | https://hdl.handle.net/10578/47612 |
| Access Level: | Acceso aberto |
| Palavra-chave: | Metastatic Castration Resistant Prostate Cancer Prostate Cancer |
| Resumo: | Background: Cabazitaxel is approved as second line treatment for metastatic castration resistant prostate cancer (mCRPC) after docetaxel failure. However, it is difficult to establish which patients will reach benefit. In this study, we aimed to analyze retrospectively clinical characteristics for cabazitaxel long responding mCRPC patients.Patients and methods: Observational, multicentric, retrospective study. All consecutive mCRPC patients receiving at least 10 cabazitaxel cycles were included from 19 centres in Spain. A descriptive analysis was performed. Overall survival (OS) was analyzed using a Kaplan-Meier model with 95% confidence intervals.Results: 81 patients were included. The median age was 64.29 years, Gleason =8 in 63.9% patients, visceral involvement in 78.8%, 42.5% of patients had bone metastases, disease-related symptoms were present in 51.8% patients. The number of events at this cut-off point of the study is 66. Median time to progression to previous docetaxel was 5.3 months. Up to 38.09% of the patients had had a time to progression to prior docetaxel longer than 20 months. Cabazitaxel was well tolerated, being asthenia main adverse event. Median OS was 26.9 months (95% CI: 16.7; 37.2). For those patients with Gleason = 7, median OS reached 29.3 months, versus 21.6 months for Gleason = 8, (p=0.4). There were no differences based on presence of symptoms and visceral metastases. However, there was a trend to a longer survival in those patients who had received previous docetaxel for a more extended period (28.6 months for 3-6 docetaxel months compared to 21.6 in < 3 months).Conclusion: This sample size is a weakness to assess prognostic factors, but there is a longer benefit in those patients with ECOG-PS 0-2 and longer treatment benefit from docetaxel. In addition, a trend to OS benefit for patients having previous treatment duration with ADT =20 months was observed; but longer follow-up is required. All patients regardless visceral metastases or symptoms achieved a meaningful benefit by receiving cabazitaxel for at least 10 cycles. |
|---|